Additionally, the 36-month beta value for STOK is 0.96. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for STOK is 41.36M and currently, short sellers hold a 21.07% ratio of that float. The average trading volume of STOK on October 09, 2024 was 546.05K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
STOK) stock’s latest price update
The stock price of Stoke Therapeutics Inc (NASDAQ: STOK) has jumped by 7.72 compared to previous close of 11.40. Despite this, the company has seen a fall of -0.73% in its stock price over the last five trading days. seekingalpha.com reported 2024-09-07 that STOK’s zorevunersen shows strong efficacy in reducing seizures but has safety concerns, particularly elevated CSF protein levels, needing further monitoring. Dravet Syndrome market potential is significant, with 35,000 patients in key regions and existing treatments costing up to $96,000 annually. STOK has a solid cash runway for 7-8 quarters, with a Phase 3 trial expected to start soon, aiming for topline data by mid-2026.
STOK’s Market Performance
STOK’s stock has fallen by -0.73% in the past week, with a monthly drop of -20.00% and a quarterly drop of -7.39%. The volatility ratio for the week is 6.23% while the volatility levels for the last 30 days are 6.67% for Stoke Therapeutics Inc The simple moving average for the past 20 days is -7.11% for STOK’s stock, with a 10.12% simple moving average for the past 200 days.
STOK Trading at -12.11% from the 50-Day Moving Average
After a stumble in the market that brought STOK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.15% of loss for the given period.
Volatility was left at 6.67%, however, over the last 30 days, the volatility rate increased by 6.23%, as shares sank -22.86% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.03% lower at present.
During the last 5 trading sessions, STOK fell by -0.73%, which changed the moving average for the period of 200-days by +152.42% in comparison to the 20-day moving average, which settled at $13.22. In addition, Stoke Therapeutics Inc saw 133.46% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at STOK starting from Ticho Barry, who sale 10,000 shares at the price of $12.06 back on Oct 01 ’24. After this action, Ticho Barry now owns 2,485 shares of Stoke Therapeutics Inc, valued at $120,648 using the latest closing price.
Skorpios Trust, the 10% Owner of Stoke Therapeutics Inc, sale 1,937,500 shares at $14.05 during a trade that took place back on Sep 19 ’24, which means that Skorpios Trust is holding 8,906,181 shares at $27,221,875 based on the most recent closing price.
Stock Fundamentals for STOK
Current profitability levels for the company are sitting at:
- -7.56 for the present operating margin
- 0.69 for the gross margin
The net margin for Stoke Therapeutics Inc stands at -6.83. The total capital return value is set at -0.44. Equity return is now at value -47.85, with -36.68 for asset returns.
Based on Stoke Therapeutics Inc (STOK), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -35.11. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -10.08.
Currently, EBITDA for the company is -110.04 million with net debt to EBITDA at 1.69. When we switch over and look at the enterprise to sales, we see a ratio of 30.27. The receivables turnover for the company is 49.7for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.67.
Conclusion
In conclusion, Stoke Therapeutics Inc (STOK) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
